Detalhe da pesquisa
1.
Divergence of mutational signatures in association with breast cancer subtype.
Mol Carcinog
; 61(11): 1056-1070, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36111610
2.
Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Breast Cancer Res
; 22(1): 28, 2020 03 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32164744
3.
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Breast Cancer Res
; 22(1): 16, 2020 02 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32014063
4.
TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients.
Cancer Immunol Immunother
; 69(7): 1315-1326, 2020 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-32198536
5.
Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors.
Cells
; 10(6)2021 06 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34201054
6.
Tumor Evolution Inferred by Patterns of microRNA Expression through the Course of Disease, Therapy, and Recurrence in Breast Cancer.
Clin Cancer Res
; 22(14): 3651-62, 2016 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-26957561